SCHEMBL5232783

SCHEMBL5232783

NC(=O)[C@]1(c2ccccc2)[CH]C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 4/20 0.41
AKR1C1 Q04828 1/20 0.41
MAOB P27338 7/20 0.41
POLB P06746 1/20 0.39
CYP3A4 P08684 1/20 0.39
PARP1 P09874 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
MAOA P21397 3/20 0.39
OPRL1 P41146 2/20 0.37
HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15529967 0.77 HDAC4 (0.39) HDAC4AKR1C1MAOBPOLBCYP3A4
SCHEMBL15542071 0.77 PARP1 (0.46) PARP1HSD11B1
SCHEMBL3265711 0.74 TDP1 (0.33) HDAC4AKR1C1POLBCYP3A4PARP1
SCHEMBL28041402 0.72 AKR1C1 (0.33) HDAC4AKR1C1MAOBPOLBCYP3A4
SCHEMBL16112625 0.72 HDAC4 (0.68) HDAC4AKR1C1LMNAOPRL1CYP2C9
SCHEMBL15541757 0.72 HDAC4 (0.47) HDAC4OPRL1HSD11B1
SCHEMBL28206407 0.71 HSD11B1 (0.33) HDAC4AKR1C1MAOBPOLBCYP3A4
SCHEMBL2722547 0.71 AKR1C1 (0.57) HDAC4AKR1C1HTTOPRL1HSD11B1
SCHEMBL501923 0.71 AKR1C1 (0.57) HDAC4AKR1C1HTTOPRL1HSD11B1
SCHEMBL1434701 0.70 HDAC9 (0.34) HDAC4AKR1C1POLBCYP3A4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867226-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF Novartis AG (CH) 2015-05-06 EP claimed
WO-2014002051-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2014-01-03 WO claimed
EP-3490986-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2019-06-05 EP disclosed
WO-2018019929-A1 PIPERIDINE CXCR7 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-02-01 WO disclosed
EP-2867226-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF Novartis AG (CH) 2015-05-06 EP disclosed
WO-2014002051-A2 COMPLEMENT PATHWAY MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2014-01-03 WO disclosed
EP-1611121-B1 PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS AVENTIS PHARMA SA (FR) 2007-08-08 EP disclosed
EP-1581505-B1 PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-01 EP disclosed